Novavax Inc. closed 64.57% short of its 52-week high of $17.81, which the company achieved on July 26th.

Novavax (NVAX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near ...

Novavax (NVAX) concluded the recent trading session at $6.41, signifying a +1.75% move from its prior day's close.

The U.S. FDA approved 14 drugs in May, a decline from 20 in April and 22 in March. That brings the year-to-date total for 2025 to 84 approvals, the second highest on record for this period, just ...

Shares of Novavax Inc. NVAX slid 7.68% to $6.49 Tuesday, on what proved to be an all-around poor trading session for the ...

Shares of San Diego-based Cidara Therapeutics Inc. (NASDAQ:CDTX) were trading at $40.41, up $19.39, or 92%, on positive top-line results from its randomized, double-blind, placebo-controlled phase IIb ...

Wall Street’s major market averages seesawed back and forth on Friday and finished mixed as Federal Reserve Governor ...

Novavax has experienced a notable decline in its stock price over the past week, dropping by 8.82%. This downturn comes amidst a challenging landscape for the company, as Citi ini ...

Vaccine businesses seen as valuable parts of pharma groups but government hostility could deter future developments ...

Back in November 2023, pharmaphorum travelled to Uppsala, Sweden, for a Novavax press conference, the company celebrating a decade of doing what it does best: vaccines. From COVID-19 to malaria ...

In the wake of Robert F. Kennedy Jr.’s abrupt revamp of the CDC’s Advisory Committee on Immunization Practices, details from ...